D Molecular Therapeutics reported its experimental gene therapy demonstrated a nearly 90% reduction in the need for ...

The drop in interest rate is slightly bigger than anticipated and good news for the biotech industry, but little will change ...

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

Job security is a hot topic among biopharma professionals. A career coach offers advice for how to evaluate and build it up ...

Infusions of Vertex and CRISPR Therapeutics’ Casgevy and bluebird bio’s Lyfgenia have begun; Moderna targets 10 approvals ...

Summit Therapeutics’ ivonescimab has the potential to challenge Merck’s blockbuster checkpoint inhibitor in non-small cell ...

Vertex said sickle cell patients had not yet received infusions of its gene therapy Casgevy. That’s now changed, as the ...

If Johnson & Johnson refuses to scrap its proposed changes to the 340B drug pricing for hospitals, it risks the termination ...

In metabolic dysfunction-associated steatotic liver disease, a retrospective analysis shows that patients on GLP-1 receptor ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Boehringer Ingelheim’s investigational compound nerandomilast, which targets the PDE4B enzyme involved in fibrosis and ...

Despite meeting the primary endpoint in a Phase III study, two patients treated with Merck and Daiichi Sankyo’s experimental ...